IRIS
DIGIACOMO, GRAZIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 849
EU - Europa 721
AS - Asia 233
AF - Africa 11
OC - Oceania 1
Totale 1.815
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 848
IT - Italia 331
CN - Cina 154
IE - Irlanda 153
SE - Svezia 102
SG - Singapore 44
DE - Germania 35
BE - Belgio 24
FR - Francia 14
IN - India 13
CI - Costa d'Avorio 11
AT - Austria 9
FI - Finlandia 9
TR - Turchia 9
CZ - Repubblica Ceca 7
NL - Olanda 7
UA - Ucraina 7
VN - Vietnam 6
GB - Regno Unito 5
RO - Romania 5
CH - Svizzera 3
JP - Giappone 3
LT - Lituania 2
MK - Macedonia 2
PK - Pakistan 2
CA - Canada 1
ES - Italia 1
HR - Croazia 1
HU - Ungheria 1
IR - Iran 1
KR - Corea 1
LU - Lussemburgo 1
NZ - Nuova Zelanda 1
PL - Polonia 1
SI - Slovenia 1
Totale 1.815
Salva come PNG Salva come JPEG
Città #
Ann Arbor 234
Dublin 153
Chandler 148
Parma 71
Ashburn 48
Shanghai 44
Dearborn 42
Milan 23
Singapore 23
Modena 22
Nanjing 21
Princeton 21
New York 20
Chicago 19
Redmond 17
Boardman 16
Bremen 16
Los Angeles 15
Beijing 12
Wayne 12
Abidjan 11
Wilmington 10
Helsinki 9
Izmir 9
San Mateo 9
Shenyang 9
Vienna 9
Des Moines 8
Jinan 8
Reggio Emilia 8
Woodbridge 8
Amsterdam 7
Binche 7
Brussels 7
Dong Ket 6
Follonica 6
Fremont 6
Leuven 6
Nanchang 6
Rome 6
Seattle 6
Hebei 5
Bologna 4
Florence 4
Hefei 4
Mons 4
Neviano degli Arduini 4
Norwalk 4
Salsomaggiore Terme 4
Soliera 4
Alvignano 3
Brescia 3
Brno 3
Castellarano 3
Coimbatore 3
Fairfield 3
Falls Church 3
Fuzhou 3
Grafing 3
Houston 3
Jiaxing 3
Kunming 3
Ningbo 3
Prata Di Pordenone 3
Pune 3
Rubiera 3
Savignano sul Rubicone 3
Taiyuan 3
Tianjin 3
Trento 3
Verona 3
Augusta 2
Bergamo 2
Campi Bisenzio 2
Carpenedolo 2
Casalgrande 2
Frankfurt am Main 2
Galatina 2
Guangzhou 2
Haikou 2
Jacksonville 2
Karak 2
Kaunas 2
Leawood 2
Maranello 2
Monmouth Junction 2
Montegaldella 2
Mumbai 2
Munich 2
Múggia 2
Paris 2
Pesaro 2
Phoenix 2
Ravenna 2
Redwood City 2
Rimini 2
Rosate 2
Rottofreno 2
Saviano 2
Skopje 2
Totale 1.296
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 200
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 121
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 117
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 101
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 89
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 87
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 84
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 73
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 69
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 68
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 64
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 62
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 60
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 59
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 59
PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment 55
Biological hallmarks and new therapeutic approaches for the treatment of pdac 51
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 50
PD-L1 OVEREXPRESSION INDUCES ANGIOGENIC CYTOKINE SECRETION AND ENDOTHELIAL CELL MIGRATION VIA STAT SIGNALLING. 49
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 48
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 42
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 42
Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells 41
Fibronectin induces macrophage migration through a SFK-FAK/CSF-1R pathway 40
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 34
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 31
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition 30
Prostaglandin E2 transactivates the colony-stimulating factor-1 receptor and synergizes with Colony-stimulating factor-1 in the induction of macrophage migration via the mitogen-activated protein kinase ERK1/2 29
State of the art and perspectives in pediatric hepatocellular carcinoma 24
Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies 2
Totale 1.881
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.666
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.666
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020303 29 18 7 11 17 48 56 15 30 39 18 15
2020/2021256 8 14 13 31 25 14 21 27 28 14 28 33
2021/2022176 22 13 24 8 3 3 28 4 11 8 8 44
2022/2023619 44 56 45 39 48 58 12 60 198 6 36 17
2023/2024390 14 23 21 14 48 56 33 25 12 32 55 57
2024/202528 28 0 0 0 0 0 0 0 0 0 0 0
Totale 1.881